Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy.
CEINGE Biotecnologie Avanzate, Napoli, Italy.
Cancer Res. 2022 Apr 1;82(7):1193-1207. doi: 10.1158/0008-5472.CAN-20-3788.
Noncoding cis-regulatory variants have gained interest as cancer drivers, yet progress in understanding their significance is hindered by the numerous challenges and limitations of variant prioritization. To overcome these limitations, we focused on active cis-regulatory elements (aCRE) to design a customized panel for the deep sequencing of 56 neuroblastoma tumor and normal DNA sample pairs. To search for driver mutations, aCREs were defined by reanalysis of H3K27ac chromatin immunoprecipitation sequencing peaks in 25 neuroblastoma cell lines. These regulatory genomic regions were tested for an excess of somatic mutations and assessed for statistical significance using a global approach that accounted for chromatin accessibility and replication timing. Additional validation was provided by whole genome sequence analysis of 151 neuroblastomas. Analysis of HiC data determined the presence of candidate target genes interacting with mutated regions. An excess of somatic mutations in aCREs of diverse genes were identified, including IPO7, HAND2, and ARID3A. CRISPR-Cas9 editing was utilized to assess the functional consequences of mutations in the IPO7-aCRE. Patients with noncoding mutations in aCREs showed inferior overall and event-free survival independent of age at diagnosis, stage, risk stratification, and MYCN status. Expression of aCRE-interacting genes correlated strongly with negative prognostic markers and low survival rates. Moreover, a convergence between the biological functions of aCRE target genes and transcription factors with mutated binding motifs was associated with embryonic development and immune system response. Overall, this strategy enabled the identification of somatic mutations in regulatory elements that collectively promote neuroblastoma tumorigenesis.
Assessment of noncoding cis-regulatory variants and long-range interaction data highlight the combined effect of somatic mutations in regulatory elements in driving neuroblastoma.
非编码顺式调控变异体已成为癌症驱动因素的研究热点,但由于变异体优先级确定的众多挑战和限制,对其意义的理解进展缓慢。为了克服这些限制,我们专注于活性顺式调控元件(aCRE),设计了一个定制面板,用于对 56 对神经母细胞瘤肿瘤和正常 DNA 样本进行深度测序。为了寻找驱动突变,我们通过重新分析 25 种神经母细胞瘤细胞系中的 H3K27ac 染色质免疫沉淀测序峰来定义 aCRE。这些调控基因组区域被检测是否存在体细胞突变过多,并使用全局方法评估统计显著性,该方法考虑了染色质可及性和复制时间。通过对 151 个神经母细胞瘤的全基因组序列分析提供了额外的验证。HiC 数据的分析确定了候选靶基因与突变区域相互作用的存在。在包括 IPO7、HAND2 和 ARID3A 在内的多种基因的 aCRE 中发现了体细胞突变过多。利用 CRISPR-Cas9 编辑来评估 IPO7-aCRE 中的突变的功能后果。具有 aCRE 非编码突变的患者,无论诊断时的年龄、分期、风险分层和 MYCN 状态如何,总生存和无事件生存均较差。aCRE 相互作用基因的表达与预后不良标志物和低生存率密切相关。此外,aCRE 靶基因的生物学功能和具有突变结合基序的转录因子之间的趋同与胚胎发育和免疫系统反应有关。总体而言,这种策略能够鉴定出调控元件中的体细胞突变,这些突变共同促进神经母细胞瘤的发生。
对非编码顺式调控变异体和长程相互作用数据的评估突出了调控元件中体细胞突变在驱动神经母细胞瘤中的综合作用。